ALK and breast carcinoma: In both ovarian and breast cancer PARP inhibitor-resistant xenograft models, mice treated with the combination of PARP and ALK inhibitors demonstrated improved survival compared with mice treated with monotherapy (Fig. 6a–d, right panels).